Physical frailty (PF) and sarcopenia are major health issues in geriatric populations, given their high prevalence and association with several adverse outcomes. Nevertheless, the lack of an univocal operational definition for the two conditions has so far hampered their clinical implementation. Existing definitional ambiguities of PF and sarcopenia, together with their complex underlying pathophysiology, also account for the absence of robust biomarkers that can be used for screening, diagnostic and/or prognostication purposes. This review provides an overview of currently available biological markers for PF and sarcopenia, as well as a critical appraisal of strengths and weaknesses of traditional procedures for biomarker development in the field. A novel approach for biomarker identification and validation, based on multivariate methodologies, is also discussed. This strategy relies on the multidimensional modeling of complementary biomarkers to cope with the phenotypical and pathophysiological complexity of PF and sarcopenia. Biomarkers identified through the implementation of multivariate strategies may be used to support the detection of the two conditions, track their progression over time or in response to interventions, and reveal the onset of complications (e.g., mobility disability) at a very early stage.

Biomarkers for physical frailty and sarcopenia / Calvani, Riccardo; Marini, Federico; Cesari, Matteo; Tosato, Matteo; Picca, Anna; Anker, Stefan D.; von Haehling, Stephan; Miller, Ram R.; Bernabei, Roberto; Landi, Francesco; Marzetti, Emanuele. - In: AGING CLINICAL AND EXPERIMENTAL RESEARCH. - ISSN 1594-0667. - STAMPA. - 29:1(2017), pp. 29-34. [10.1007/s40520-016-0708-1]

Biomarkers for physical frailty and sarcopenia

MARINI, Federico;
2017

Abstract

Physical frailty (PF) and sarcopenia are major health issues in geriatric populations, given their high prevalence and association with several adverse outcomes. Nevertheless, the lack of an univocal operational definition for the two conditions has so far hampered their clinical implementation. Existing definitional ambiguities of PF and sarcopenia, together with their complex underlying pathophysiology, also account for the absence of robust biomarkers that can be used for screening, diagnostic and/or prognostication purposes. This review provides an overview of currently available biological markers for PF and sarcopenia, as well as a critical appraisal of strengths and weaknesses of traditional procedures for biomarker development in the field. A novel approach for biomarker identification and validation, based on multivariate methodologies, is also discussed. This strategy relies on the multidimensional modeling of complementary biomarkers to cope with the phenotypical and pathophysiological complexity of PF and sarcopenia. Biomarkers identified through the implementation of multivariate strategies may be used to support the detection of the two conditions, track their progression over time or in response to interventions, and reveal the onset of complications (e.g., mobility disability) at a very early stage.
2017
aging; disability; markers; multivariate analysis; physical performance; skeletal muscle
01 Pubblicazione su rivista::01a Articolo in rivista
Biomarkers for physical frailty and sarcopenia / Calvani, Riccardo; Marini, Federico; Cesari, Matteo; Tosato, Matteo; Picca, Anna; Anker, Stefan D.; von Haehling, Stephan; Miller, Ram R.; Bernabei, Roberto; Landi, Francesco; Marzetti, Emanuele. - In: AGING CLINICAL AND EXPERIMENTAL RESEARCH. - ISSN 1594-0667. - STAMPA. - 29:1(2017), pp. 29-34. [10.1007/s40520-016-0708-1]
File allegati a questo prodotto
File Dimensione Formato  
Calvani_Biomarkers_2017.pdf

solo utenti autorizzati

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 550.24 kB
Formato Adobe PDF
550.24 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/974349
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 50
social impact